Summary
Orphan drug legislation passed in the USA in 1983 and in Europe in 1999 has encouraged biotechnology companies to develop treatments for diseases that the industry previously ignored because they affect only small numbers of people and promised only limited profitability. Incentives, exclusivity and the freedom to charge sufficient to cover development costs has led to a niche market, and patients with lysosomal storage disorders have been one of the main beneficiaries of these developments. The recombinant production of highly purified enzymes that are modified to improve tissue targeting has been a direct result of this legislation. The spectacular clinical and financial success of Cerezyme (and previously Ceredase, Genzyme) for the treatment of Gaucher disease has led to the development of enzyme replacement treatment(s) for Fabry disease and mucopolysaccharidoses types I and VI. A number of other enzyme replacement therapies are at an earlier stage in development and the next 12 months could see the launch of therapies for mucopolysaccharidosis type II and Pompe disease. Like all medical treatments, this approach has some limitations. Not all patients are suitable for treatment, some organs and tissues are corrected more readily than others, and there are problems with gauging efficacy in these highly variable disorders. Finally, the therapies are expensive, limiting access to patients from those countries that are able to afford expensive health care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
An Y, Young SP, Kishmani PS, et al (2005) Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85: 247–254.
Auclair D, Hopwood JJ, Brooks DA, Lemontt JF, Crawley AC (2003) Replacement therapy in mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab 78: 163–174.
Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA87: 1913–1916.
Brady RO, Barton (1991) Enzyme replacement therapy for type 1 Gaucher disease. In: Desnick RJ, ed. Treatment of Genetic Diseases.New York: Churchill Livingstone, 153–168.
Charrow J, Andersson HC, Kaplan P, et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med160: 2835–2843.
Cox TM (2001) Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis24(Supplement 2): 106–121.
Cox TM (2005) Biomarkers in lysosomal storage diseases: a review. Acta Paediatr94: 39–42.
Deegan PB, Moran MT, McFarlane I, et al (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35: 259–267.
Desnick RJ (ed.) (1980) Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss.
Dumas HM, Fragala MA, Haley SM, et al (2004) Physical performance testing in mucopolysaccharidosis I: a pilot study. Pediatr Rehabil 7: 125–131.
Fuller M, Meikle PJ, Hopwood JJ (2004) Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology14: 443–450.
Fuller M, Brooks DA, Evangelista M, et al (2005) Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab84: 18–24.
Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A (2004) New directions in the treatment of Gaucher disease. Trends Pharmacol Sci25: 147–151.
Grabowski GA, Barton NW, Pastores G, et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med122: 33–39.
Hobbs JR, Hugh-Jones K, Barrett AJ, et al (1981) Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone marrow transplantation. Lancet2(8249): 709–712.
Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al (1995) Allogenic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet345(8962): 1382–1383.
Jeyakumar M, Smith DA, Williams IM, et al (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol56: 642–649.
Kakkis ED, McEntee MF, Schmidtchen A, et al (1996) Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58: 156–167.
Kaplan A, Achord DT, Sly WS (1977) Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc Natl Acad Sci. USA 74: 1016–1030.
Linthorst GE, Hollak CE, Donker-Koopman WE, Srijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66: 1589–1595.
Mehta A, Ricci R, Widmer U, et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest34: 236–242.
Simonaro CM, Haskins ME, Schuchman EH (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest81: 1319–1328.
Sweidler SJ, Beck M, Bajbouj M, et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux—Lamy syndrome). Am J Med Genet134: 144–150.
Tomatsu S, Okamura K, Maeda H, et al (2005) Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 28: 187–202.
Van den Hout HMP, Hop W, van Diggelen OP, et al (2005) Pediatrics112: 332–340.
Wasserstein MP, Desnick RJ, Schuchmann EH, et al (2004) The natural history of type B Niemann—Pick disease: results from a 10-year longitudinal study. Pediatrics114: 672–677.
Weinreb NJ, Charrow J, Andersson HC, et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type I Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am J Med113: 112–119.
Whybra C, Kampmann C, Krummenauer F, et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson—Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet65: 299–307.
Young E, Mills K, Morris P, et al (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr94: 51–54.
Zimran A, Gross E, West C, et al (1989) Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet2: 349–352.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Jean-Marie Saudubray
Competing interests: None declared
Rights and permissions
About this article
Cite this article
Wraith, J.E. Limitations of enzyme replacement therapy: Current and future. J Inherit Metab Dis 29, 442–447 (2006). https://doi.org/10.1007/s10545-006-0239-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10545-006-0239-6